Atalie C Thompson, MD
Ophthalmology · Winston Salem
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Wake Forest University Health Sciences · 2,633 clinicians in this group
Hospitals listed: North Carolina Baptist Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Thompson’s office at (336) 716-2734 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- North Carolina Baptist HospitalWinston-Salem, NCAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesHome of Wake Forest Baptist Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.45 (0.98 to 1.91) · 9,389 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.242, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.353, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 8.6 (7.1 to 10.6) · 706 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for North Carolina Baptist Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.45 (0.98 to 1.91) · 9,389 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.353 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.6 (7.1 to 10.6) · 706 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.2 to 1.74) · 2,706 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.87 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.03 (119.34 to 192.72) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.6 · 239 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.3 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 297 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 631 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 7,258 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.29) · 10,835 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.15 to 0.51) · 11,325 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.16 (1.65 to 4.67) · 4,146 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.19) · 1,971 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.02 to 3.11) · 3,871 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.83 (3.98 to 11.68) · 1,896 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.48 (1.04 to 5.92) · 2,029 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.45 to 3.03) · 1,078 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 38 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.754 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.126 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.035 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.314 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14 · 713 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 1,362 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.5 · 377 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.9 · 613 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26 · 317 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 774 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (4.3 to 7) · 706 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 39 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 288 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.6 to 16.4) · 981 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,479 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$24,127
Medicare paid this office $24,127 for 88 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 67 | $6,344 | $64 |
| Exam of visual field with extended testing | 56 | $1,383 | $18 |
| New patient visit (45+ min) | 11 | $990 | $90 |
| Imaging of optic nerve | 58 | $901 | $15 |
| Exam of the internal drainage system of eye | 22 | $303 | $14 |
See all 6 services
| Return visit (30+ min) | 67 | $6,344 | $64 |
| Exam of visual field with extended testing | 56 | $1,383 | $18 |
| New patient visit (45+ min) | 11 | $990 | $90 |
| Imaging of optic nerve | 58 | $901 | $15 |
| Exam of the internal drainage system of eye | 22 | $303 | $14 |
| Ultrasound scan of cornea to determine thickness | 17 | $92 | $5 |
Procedures Medicare counted
| Cataract surgery | 15 | More than 38% of doctors who do this |
Who their Medicare patients are
88 Original Medicare patients in 2024. Average age 75 · Women 64% · Health risk score 1.32. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 74% · Chronic kidney disease 30% · Diabetes 28% · Depression 25% · Coronary heart disease 19% · COPD 16% · Cancer 13% · Atrial fibrillation 13%.
The office billed $109,484, Medicare allowed $31,508 and paid $24,127; for 348 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 88 | 348 | 75 | 1.32 | $109,484 | $24,127 |
| 2023 | 68 | 297 | 77 | 1.35 | $82,836 | $18,520 |
| 2022 | 62 | 289 | 76 | 1.16 | $107,226 | $24,613 |
| 2021 | 61 | 244 | 75 | 0.96 | $123,140 | $22,027 |
| 2020 | 76 | 167 | 74 | 1.27 | $100,484 | $15,261 |
| 2019 | 147 | 215 | 74 | 1.19 | $84,754 | $16,739 |
| 2018 | 48 | 57 | 71 | 1.24 | $23,131 | $5,259 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 51 | $5,658 | $66 |
| New patient visit (45+ min) | 14 | $1,211 | $87 |
| Exam of visual field with extended testing | 51 | $1,052 | $18 |
| Imaging of optic nerve | 46 | $678 | $14 |
| Exam of the internal drainage system of eye | 20 | $293 | $14 |
| Ultrasound scan of cornea to determine thickness | 21 | $106 | $5 |
2022: 6 services
| Return visit (30+ min) | 46 | $5,779 | $68 |
| New patient visit (45+ min) | 17 | $1,345 | $79 |
| Exam of visual field with extended testing | 34 | $756 | $17 |
| Imaging of optic nerve | 39 | $569 | $14 |
| Exam of the internal drainage system of eye | 18 | $219 | $12 |
| Ultrasound scan of cornea to determine thickness | 23 | $109 | $5 |
2021: 7 services
| Return visit (30+ min) | 20 | $2,419 | $78 |
| Established patient problem focused exam of visual system | 14 | $693 | $46 |
| Established patient complete exam of visual system | 11 | $666 | $61 |
| Exam of visual field with extended testing | 20 | $487 | $21 |
| Imaging of optic nerve | 27 | $462 | $17 |
| Exam of the internal drainage system of eye | 15 | $240 | $16 |
| Ultrasound scan of cornea to determine thickness | 19 | $118 | $6 |
2020: 4 services
| Established patient complete exam of visual system | 33 | $2,709 | $82 |
| Established patient problem focused exam of visual system | 34 | $1,951 | $48 |
| Exam of visual field with extended testing | 16 | $660 | $39 |
| Imaging of optic nerve | 15 | $356 | $24 |
2019: 5 services
| Established patient problem focused exam of visual system | 63 | $4,087 | $60 |
| Creation of shunt to improve eye fluid flow using tissue graft | 14 | $2,651 | $189 |
| Established patient complete exam of visual system | 33 | $2,157 | $63 |
| Exam of visual field with extended testing | 15 | $708 | $44 |
| Imaging of optic nerve | 20 | $504 | $25 |
2018: 2 services
| Creation of shunt to improve eye fluid flow using tissue graft | 13 | $1,677 | $129 |
| Established patient problem focused exam of visual system | 18 | $1,267 | $67 |
Medicaid work
$529 in 2024
Medicaid paid $529 for 50 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Hospital outpatient clinic visit for assessment and management of a patient | 50 | $529 |
| 2024 | 50 | 1 | 13 | $529 |
Drugs they prescribed that Part D paid
$76,672
Pharmacies billed $76,672 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,410) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
1,117 generic and 293 brand-name prescriptions · $76,672 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rhopressa | 30 | $13,902 | $463 |
| Lumigan | 30 | $8,113 | $270 |
| Brimonidine | 183 | $6,546 | $36 |
| Latanoprost | 470 | $4,870 | $10 |
| Alphagan P | 11 | $4,551 | $414 |
See all 14 drugs
| Rhopressa | 30 | $13,902 | $463 |
| Lumigan | 30 | $8,113 | $270 |
| Brimonidine | 183 | $6,546 | $36 |
| Latanoprost | 470 | $4,870 | $10 |
| Alphagan P | 11 | $4,551 | $414 |
| Dorzolamide-Timolol | 319 | $4,427 | $14 |
| Combigan | 11 | $2,212 | $201 |
| Brinzolamide | 13 | $1,658 | $128 |
| Prednisolone Acetate | 50 | $1,639 | $33 |
| Dorzolamide | 70 | $1,563 | $22 |
| Travoprost | 14 | $1,173 | $84 |
| Timolol Maleate | 91 | $730 | $8 |
| Ketorolac Tromethamine | 19 | $699 | $37 |
| Carteolol | 13 | $158 | $12 |
Year by year
| 2024 | 1,410 | 184 | 0% (0) | 21% | $76,672 |
| 2023 | 1,121 | 141 | 0% (0) | 25% | $95,313 |
| 2022 | 669 | 122 | 0% (0) | 26% | $48,315 |
| 2021 | 394 | 98 | 0% (0) | 30% | $30,496 |
| 2020 | 710 | 241 | 0% (0) | 34% | $78,848 |
| 2019 | 2,840 | 794 | None | 35% | $273,129 |
| 2018 | 837 | 424 | None | 46% | $74,611 |
| 2017 | 38 | 12 | None | 55% | $3,270 |
| 2016 | 66 | 30 | None | 48% | $2,043 |
| 2015 | 54 | 18 | 0% (0) | 20% | $1,935 |
| 2014 | 36 | 11 | 0% (0) | None | $1,653 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Rhopressa | 41 | $21,742 | $530 |
| Lumigan | 31 | $8,373 | $270 |
| Latanoprost | 357 | $7,504 | $21 |
| Alphagan P | 14 | $7,371 | $527 |
| Dorzolamide-Timolol | 216 | $6,071 | $28 |
| Brimonidine | 152 | $5,246 | $35 |
| Vyzulta | 12 | $4,623 | $385 |
| Brimonidine Tartrate-Timolol | 17 | $3,615 | $213 |
| Combigan | 11 | $3,498 | $318 |
| Dorzolamide | 69 | $1,869 | $27 |
| Prednisolone Acetate | 34 | $1,261 | $37 |
| Timolol Maleate | 73 | $613 | $8 |
| Ketorolac Tromethamine | 17 | $458 | $27 |
2022: 9 drugs
| Rhopressa | 27 | $10,793 | $400 |
| Dorzolamide-Timolol | 162 | $5,103 | $31 |
| Latanoprost | 192 | $4,857 | $25 |
| Brimonidine | 82 | $4,709 | $57 |
| Brimonidine Tartrate-Timolol | 14 | $2,756 | $197 |
| Prednisolone Acetate | 36 | $1,508 | $42 |
| Dorzolamide | 44 | $957 | $22 |
| Ketorolac Tromethamine | 24 | $700 | $29 |
| Timolol Maleate | 38 | $246 | $6 |
2021: 8 drugs
| Combigan | 12 | $3,777 | $315 |
| Latanoprost | 129 | $2,493 | $19 |
| Brimonidine | 34 | $2,310 | $68 |
| Dorzolamide-Timolol | 73 | $2,252 | $31 |
| Prednisolone Acetate | 30 | $1,428 | $48 |
| Dorzolamide | 18 | $506 | $28 |
| Ciprofloxacin | 12 | $130 | $11 |
| Timolol Maleate | 17 | $56 | $3 |
2020: 11 drugs
| Lumigan | 28 | $12,101 | $432 |
| Restasis | 15 | $10,324 | $688 |
| Combigan | 24 | $6,101 | $254 |
| Brimonidine | 80 | $5,670 | $71 |
| Azopt | 11 | $4,811 | $437 |
| Latanoprost | 206 | $4,399 | $21 |
| Dorzolamide-Timolol | 80 | $3,954 | $49 |
| Dorzolamide | 66 | $2,382 | $36 |
| Prednisolone Acetate | 26 | $1,367 | $53 |
| Doxycycline Hyclate | 12 | $776 | $65 |
| Timolol Maleate | 49 | $551 | $11 |
2019: 28 drugs
| Lumigan | 86 | $30,869 | $359 |
| Combigan | 94 | $26,790 | $285 |
| Alphagan P | 70 | $22,601 | $323 |
| Azopt | 54 | $20,745 | $384 |
| Restasis | 20 | $19,324 | $966 |
| Travatan Z | 56 | $18,784 | $335 |
| Latanoprost | 807 | $17,024 | $21 |
| Dorzolamide-Timolol | 277 | $14,649 | $53 |
| Brimonidine | 349 | $14,226 | $41 |
| Xiidra | 18 | $9,843 | $547 |
| Methazolamide | 18 | $8,929 | $496 |
| Dorzolamide | 207 | $7,008 | $34 |
| Rhopressa | 19 | $6,867 | $361 |
| Prednisolone Acetate | 147 | $6,624 | $45 |
| Simbrinza | 22 | $5,951 | $270 |
| Dorzolamide-Timolol | 22 | $4,856 | $221 |
| Timolol Maleate | 286 | $4,570 | $16 |
| Vyzulta | 12 | $4,531 | $378 |
| Acetazolamide | 21 | $3,627 | $173 |
| Durezol | 18 | $3,532 | $196 |
| Cosopt Pf | 14 | $2,406 | $172 |
| Fluorometholone | 14 | $1,473 | $105 |
| Apraclonidine | 11 | $644 | $59 |
| Ketorolac Tromethamine | 16 | $472 | $30 |
| Ofloxacin | 24 | $325 | $14 |
| Polymyxin B Sul-Trimethoprim | 22 | $210 | $10 |
| Ciprofloxacin | 15 | $152 | $10 |
| Levobunolol | 12 | $67 | $6 |
2018: 16 drugs
| Travatan Z | 26 | $9,700 | $373 |
| Restasis | 13 | $9,595 | $738 |
| Alphagan P | 26 | $7,746 | $298 |
| Lumigan | 27 | $7,149 | $265 |
| Combigan | 20 | $5,401 | $270 |
| Azopt | 12 | $4,958 | $413 |
| Prednisolone Acetate | 105 | $4,003 | $38 |
| Brimonidine | 80 | $3,354 | $42 |
| Latanoprost | 178 | $3,311 | $19 |
| Dorzolamide-Timolol | 87 | $2,855 | $33 |
| Timolol Maleate | 62 | $1,321 | $21 |
| Dorzolamide | 43 | $1,219 | $28 |
| Ketorolac Tromethamine | 13 | $321 | $25 |
| Ofloxacin | 21 | $283 | $13 |
| Erythromycin | 18 | $186 | $10 |
| Polymyxin B Sul-Trimethoprim | 20 | $172 | $9 |
2016: 2 drugs
| Prednisolone Acetate | 27 | $1,047 | $39 |
| Polymyxin B Sul-Trimethoprim | 11 | $107 | $10 |
Money from drug and device companies
$2,040 in 2022
| 2022 | 2 | 3 | $2,000 | $2,040 |
| 2019 | 1 | 1 | None | $100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Topcon Medical Systems | Imovifa | $2,021 | 2 payments
|
| Glaukos | Istent | $19 | 1 payment
|
See all 3 published payments
| Topcon Medical Systems | Consulting · 2022-11-02 | Imovifa | $2,000 |
| Topcon Medical Systems | Travel · 2022-11-02 | None | $21 |
| Glaukos | Meals · 2022-05-18 | Istent | $19 |
See earlier years (2019)
2019: $100
| Aerie Pharmaceuticals | Rhopressa | $100 | 1 payment
|
Professional record
- NPI
- 1366852303
- Licence
- NC 2018-00389
- Trained
- Stanford University School of Medicine, 2014
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0009X (207WX0009X)
- Mailing address
- 1023 Oak Blossom Way, Whitsett, NC, 27377
- NPI first listed
- 2014-04-29
- NPI last updated
- 2019-08-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: Durham VA Medical Center 508 Fulton Street, Durham, NC, 27710 · 291 Campus Dr, Stanford, CA, 94305